SI2525798T1 - Anesthetic formulation - Google Patents
Anesthetic formulation Download PDFInfo
- Publication number
- SI2525798T1 SI2525798T1 SI201131342T SI201131342T SI2525798T1 SI 2525798 T1 SI2525798 T1 SI 2525798T1 SI 201131342 T SI201131342 T SI 201131342T SI 201131342 T SI201131342 T SI 201131342T SI 2525798 T1 SI2525798 T1 SI 2525798T1
- Authority
- SI
- Slovenia
- Prior art keywords
- composition
- cyclodextrin
- anesthetic
- sedative
- alphaxalon
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 20
- 230000003444 anaesthetic effect Effects 0.000 title claims abstract 12
- 238000009472 formulation Methods 0.000 title claims abstract 3
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract 13
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract 8
- 150000003431 steroids Chemical class 0.000 claims abstract 7
- 239000000932 sedative agent Substances 0.000 claims abstract 5
- 230000001624 sedative effect Effects 0.000 claims abstract 5
- -1 sulfoalkyl ether Chemical compound 0.000 claims abstract 3
- 239000001116 FEMA 4028 Substances 0.000 claims 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims 3
- 229960004853 betadex Drugs 0.000 claims 3
- QRJOQYLXZPQQMX-FWROMSNXSA-N acetic acid [2-[(3R,5S,8S,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethyl-11-oxo-1,2,3,4,5,6,7,8,9,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] ester Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)COC(=O)C)[C@@]2(C)CC1=O QRJOQYLXZPQQMX-FWROMSNXSA-N 0.000 claims 2
- XWYBFXIUISNTQG-VKMGZQQJSA-N alfadolone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CC[C@H]21 XWYBFXIUISNTQG-VKMGZQQJSA-N 0.000 claims 2
- 229950000888 alfadolone acetate Drugs 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 claims 1
- 206010002091 Anaesthesia Diseases 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 206010039897 Sedation Diseases 0.000 claims 1
- 150000005215 alkyl ethers Chemical class 0.000 claims 1
- 230000037005 anaesthesia Effects 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 230000002232 neuromuscular Effects 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 230000036280 sedation Effects 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 229940124326 anaesthetic agent Drugs 0.000 abstract 2
- 229940097362 cyclodextrins Drugs 0.000 abstract 2
- 238000012377 drug delivery Methods 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 1
- 239000003193 general anesthetic agent Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Nanotechnology (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Anesthesiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29724910P | 2010-01-21 | 2010-01-21 | |
| US38531810P | 2010-09-22 | 2010-09-22 | |
| EP11734245.1A EP2525798B1 (en) | 2010-01-21 | 2011-01-19 | Anaesthetic formulation |
| PCT/AU2011/000050 WO2011088503A1 (en) | 2010-01-21 | 2011-01-19 | Anaesthetic formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2525798T1 true SI2525798T1 (en) | 2018-01-31 |
Family
ID=44306295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201131342T SI2525798T1 (en) | 2010-01-21 | 2011-01-19 | Anesthetic formulation |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US8697678B2 (https=) |
| EP (1) | EP2525798B1 (https=) |
| JP (1) | JP5930311B2 (https=) |
| KR (1) | KR101747476B1 (https=) |
| CN (1) | CN102802635B (https=) |
| AU (1) | AU2011207103B2 (https=) |
| BR (1) | BR112012017800B1 (https=) |
| CA (1) | CA2786762C (https=) |
| CL (1) | CL2012002032A1 (https=) |
| CY (1) | CY1119947T1 (https=) |
| DK (1) | DK2525798T3 (https=) |
| ES (1) | ES2646829T3 (https=) |
| GB (2) | GB2491491B (https=) |
| HR (1) | HRP20171699T1 (https=) |
| HU (1) | HUE035441T2 (https=) |
| LT (1) | LT2525798T (https=) |
| NO (1) | NO2525798T3 (https=) |
| NZ (1) | NZ601255A (https=) |
| PL (1) | PL2525798T3 (https=) |
| PT (1) | PT2525798T (https=) |
| RS (1) | RS56576B1 (https=) |
| RU (1) | RU2574022C2 (https=) |
| SG (1) | SG181997A1 (https=) |
| SI (1) | SI2525798T1 (https=) |
| SM (1) | SMT201700518T1 (https=) |
| WO (1) | WO2011088503A1 (https=) |
| ZA (1) | ZA201205370B (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7858609B2 (en) | 2005-11-28 | 2010-12-28 | Marinus Pharmaceuticals | Solid ganaxolone formulations and methods for the making and use thereof |
| WO2013043985A1 (en) | 2011-09-23 | 2013-03-28 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| SG11201401597TA (en) * | 2011-11-29 | 2014-05-29 | Jurox Pty Ltd | Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug |
| EP2806877B2 (en) * | 2012-01-23 | 2025-01-29 | Sage Therapeutics, Inc. | Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin |
| US20140050789A1 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| ES3056529T3 (en) | 2012-11-09 | 2026-02-23 | Drawbridge Pharmaceuticals Pty Ltd | Neuroactive steroids and their use to facilitate neuroprotection |
| AU2013352141B2 (en) * | 2012-11-30 | 2018-04-05 | The Regents Of The University Of California | Anticonvulsant activity of steroids |
| WO2015134670A1 (en) * | 2014-03-05 | 2015-09-11 | Mingbao Zhang | Deuterated ganaxolone derivatives |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| CA2973140C (en) * | 2015-02-06 | 2025-09-16 | Marinus Pharmaceuticals, Inc. | Intravenous Ganaxolone Formulations and Their Use in the Treatment of Status Epilepticus and Other Epileptic Disorders |
| AR105044A1 (es) * | 2015-06-18 | 2017-08-30 | Sage Therapeutics Inc | Soluciones de esteroides neuroactivos y sus métodos de uso, recipiente |
| US9585867B2 (en) | 2015-08-06 | 2017-03-07 | Charles Everett Ankner | Cannabinod formulation for the sedation of a human or animal |
| AU2016338672A1 (en) * | 2015-10-16 | 2018-04-12 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| KR20240157128A (ko) | 2016-03-08 | 2024-10-31 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드, 조성물, 및 그의 용도 |
| EP3481387A4 (en) | 2016-08-11 | 2020-04-08 | Ovid Therapeutics Inc | METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| CN111971238B (zh) | 2018-04-16 | 2022-02-18 | 川崎重工业株式会社 | 带式输送机 |
| SG11202012271VA (en) * | 2018-07-03 | 2021-01-28 | Drawbridge Pharmaceuticals Pty Ltd | Neuroactive steroids and methods of preparation |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| CN113613632A (zh) * | 2018-12-10 | 2021-11-05 | 光环科学有限责任公司 | 麻醉剂的稳定制剂和相关剂型 |
| JP7754799B2 (ja) | 2019-08-05 | 2025-10-15 | マリナス ファーマシューティカルズ， インコーポレイテッド | てんかん重積状態の治療に使用するためのガナキソロン |
| WO2021113834A1 (en) | 2019-12-06 | 2021-06-10 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating tuberous sclerosis complex |
| US11969434B1 (en) | 2022-08-29 | 2024-04-30 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
| US12186327B2 (en) | 2022-08-29 | 2025-01-07 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2062359T3 (es) * | 1989-05-24 | 1994-12-16 | Innovet Inc | Un procedimiento de preparacion de una composicion anestesica o hipnotica esteroidal hipoalergenica. |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| WO1993017711A1 (en) * | 1992-03-11 | 1993-09-16 | Australian Commercial Research & Development Limited | New cyclodextrins and new formulated drugs |
| US5472954A (en) * | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
| JP4227675B2 (ja) * | 1996-10-25 | 2009-02-18 | 康武 日地 | 神経毒軽減麻酔剤 |
| AUPQ633900A0 (en) * | 2000-03-20 | 2000-04-15 | Jurox Pty Ltd | Anaesthetic composition |
| RU2288921C2 (ru) * | 2000-12-19 | 2006-12-10 | Калифорниа Инститьют оф Текнолоджи | Композиции, содержащие комплексы включения |
| US7034013B2 (en) * | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| EP1383445A4 (en) * | 2001-03-20 | 2005-04-13 | Cydex Inc | FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN |
| IL152575A (en) * | 2002-10-31 | 2008-12-29 | Transpharma Medical Ltd | A skin-to-skin transmission system of water-insoluble drugs |
| US7858609B2 (en) * | 2005-11-28 | 2010-12-28 | Marinus Pharmaceuticals | Solid ganaxolone formulations and methods for the making and use thereof |
-
2011
- 2011-01-19 SM SM20170518T patent/SMT201700518T1/it unknown
- 2011-01-19 PL PL11734245T patent/PL2525798T3/pl unknown
- 2011-01-19 GB GB1210657.1A patent/GB2491491B/en active Active
- 2011-01-19 NZ NZ601255A patent/NZ601255A/xx not_active IP Right Cessation
- 2011-01-19 WO PCT/AU2011/000050 patent/WO2011088503A1/en not_active Ceased
- 2011-01-19 HR HRP20171699TT patent/HRP20171699T1/hr unknown
- 2011-01-19 DK DK11734245.1T patent/DK2525798T3/da active
- 2011-01-19 HU HUE11734245A patent/HUE035441T2/en unknown
- 2011-01-19 NO NO11734245A patent/NO2525798T3/no unknown
- 2011-01-19 KR KR1020127021761A patent/KR101747476B1/ko active Active
- 2011-01-19 PT PT117342451T patent/PT2525798T/pt unknown
- 2011-01-19 EP EP11734245.1A patent/EP2525798B1/en active Active
- 2011-01-19 AU AU2011207103A patent/AU2011207103B2/en active Active
- 2011-01-19 CN CN201180013975.2A patent/CN102802635B/zh not_active Expired - Fee Related
- 2011-01-19 US US13/574,201 patent/US8697678B2/en active Active
- 2011-01-19 SG SG2012050159A patent/SG181997A1/en unknown
- 2011-01-19 LT LTEP11734245.1T patent/LT2525798T/lt unknown
- 2011-01-19 SI SI201131342T patent/SI2525798T1/en unknown
- 2011-01-19 BR BR112012017800-8A patent/BR112012017800B1/pt not_active IP Right Cessation
- 2011-01-19 CA CA2786762A patent/CA2786762C/en active Active
- 2011-01-19 RS RS20171135A patent/RS56576B1/sr unknown
- 2011-01-19 GB GB1201842.0A patent/GB2484244B/en active Active
- 2011-01-19 RU RU2012134321/15A patent/RU2574022C2/ru active
- 2011-01-19 ES ES11734245.1T patent/ES2646829T3/es active Active
- 2011-01-19 JP JP2012549208A patent/JP5930311B2/ja active Active
-
2012
- 2012-07-18 ZA ZA2012/05370A patent/ZA201205370B/en unknown
- 2012-07-20 CL CL2012002032A patent/CL2012002032A1/es unknown
-
2013
- 2013-11-01 US US14/069,751 patent/US8975245B2/en active Active
-
2017
- 2017-11-07 CY CY20171101164T patent/CY1119947T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2525798T1 (en) | Anesthetic formulation | |
| CN107261152B (zh) | 包含环糊精和疏水性药物的可注射药物组合物的防腐方法 | |
| HRP20211686T1 (hr) | Formulacije intravenozne otopine sa posakonazolom, stabilizirane supstituiranim beta-ciklodekstrinom | |
| JP2013517299A5 (https=) | ||
| AU2011313852A8 (en) | Clevidipine emulsion formulations containing antimicrobial agents | |
| EP1613356A1 (en) | A fluoroquinolone aqueous formulation of a ph between 4 and 7 comprising i.a. cyclodextrin, hydroxy acid | |
| HRP20140051T1 (hr) | Farmaceutski pripravci koji sadrže imidazokinolin(amine) i njihovi derivati prikladni za lokalno davanje | |
| JP2012012418A5 (https=) | ||
| MX2015015589A (es) | Composiciones y metodos para el suministro de agentes activos hidrófobos. | |
| JP2014240439A5 (https=) | ||
| NZ588913A (en) | Liver cancer drug | |
| UA102709C2 (uk) | Протимікробна композиція | |
| JP2016505576A5 (https=) | ||
| CA2692191C (en) | Use of conjugates of hyaluronic acid in the local treatment of hyperproliferative skin diseases | |
| CO6230979A2 (es) | Uso de quitosanas para incrementar el indice de crecimiento de las uñas | |
| PH12012502454A1 (en) | Formulations including amiodarone and salts thereof and methods of their manufacture and use | |
| NZ731518A (en) | Formulations of a pi3k/mtor-inhibitor for intravenous administration | |
| EP2745856A3 (en) | Bioactive Compositions, Bioactive Eluting Devices and Methods of Use Thereof | |
| WO2010029093A3 (en) | Compositions for percutaneous administration | |
| JP2014510109A5 (https=) | ||
| WO2014122498A3 (en) | Composition of cabazitaxel and sulfobutylether beta-cyclodextrin | |
| MY150820A (en) | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance | |
| GB2474809A (en) | Conjugated suramin amino compounds for medical conditions | |
| US20160317467A1 (en) | Method of treating or preventing infection | |
| AU2013273764B2 (en) | Pharmaceutical compositions |